Increasing Prescription Drug Competition Act

Summary

Official

Increasing Prescription Drug Competition Act This bill provides that certifications in generic drug applications of certain patents involved in Risk Evaluation and Mitigation Strategy (REMS) programs have no effect upon the drug's approval. (The Food and Drug Administration sometimes requires a REMS program for certain drugs with safety risks, which may include restrictions on a...

How would you vote on this bill?

Yes No

Bill Progress

Bill has been introduced and assigned a number

Introduced(3/1/23)

Committee

Passed House

Passed Senate

President

Law